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Taxol is an antineoplastic drug which targets microtu-
bules and which has significant clinical activity in ovarian
and breast cancer, and also in lymphomas and non-small-
cell lung cancer [1]. In the early clinical trials, a high inci-
dence of acute reactions (bronchospasm, hypotension and
arrhythmias) was observed due to the vehicle Cremophor
[2]. For later clinical trials, taxol was administered with
antiallergic premedication. In these trials, neutropenia
was observed as dose-limiting toxicity. In addition, a sen-
sory neuropathy, nausea, myalgias, mucositis and alope-
cia were common. For phase II studies in solid tumors,
210 mg/m2 as a 6-hour infusion and 250 mg/m2 as a 24-
hour infusion were recommended [1]. In refractory ovar-
ian cancer, taxol could be safely administered at up to
250 mg/m2 with G-CSF support; in this study, sensory
neuropathy was the major dose-limiting toxicity [3]. In
vitro, several human leukemic cell lines were found to be
sensitive to taxol [5]. Taxol induces apoptosis in sensitive
myeloid leukemia cell lines [5, 6]. In a phase I study, taxol
was used in refractory acute leukemias. At doses of
390 mg/m2, repeated once every 3 weeks, severe mucositis
was observed [7]. At this dose, a clearance of leukemic
blasts from blood and bone marrow was observed in 2/6
patients. By analogy to vincristine, another agent target-
ing microtubules, we hypothesized that weekly adminis-
tration of a lower dose repeated 3 times might lead to
reduced side effects and enhanced antileukemic activity.
We therefore designed a phase I study, in which taxol was
administered to patients with relapsed or refractory acute
myelogenous leukemia (AML) starting with a dose of
80 mg/m2 repeated in 3 weekly intervals.
Adults (aged 116 years) were eligible for this phase I
study if they had relapsed AML or were not in complete
remission (CR) after at least 2 courses of induction treat-
ment. In addition, the likelihood of remission with stan-
dard salvage regimes (high-dose cytosine-arabinoside)
had to be !40% as judged by a duration of first remission
of less than 1 year and having received at least one prior
salvage regimen. Other eligibility criteria were: serum cre-
atinine and bilirubin each !1.6 mg/ml; Zubrod perfor-
mance status !3; no prior cisplatin, or taxotere; no major
cardiac history; at least 2 weeks from last prior therapy
and full recovery from any toxic effects. Taxol was sup-
plied by the Division of Cancer Treatment of the National
Cancer Institute, Bethesda, Md.
The probability of obtaining CR was calculated ac-
cording to a statistical model based on 314 patients with
relapsed AML [8]. Details of the patients are given in
table 1.
Taxol was started in the first 3 patients at a dose of
80 mg/m2 over 24 h by intravenous infusion on days, 1, 8,
and 15. Premedication consisted of dexamethasone 20
mg i.v. 14 and 7 h prior to beginning taxol and diphenhy-
dramine and ranitidine 50 mg 30 min prior to taxol. A
dose escalation was planned in the steps of 100, 125, 160
and 200 mg/m2 (3 doses each) if no excessive toxicity
developed in the first 3 patients treated at the previous
dosage level. A patient was to be removed from the study
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Table 1. Patient characteristics, taxol dose, side effects and clearance of leukemic blasts
Pat. Age
years
Cytogenetics Duration
CR 1, weeks
Salvage
n
Pred. prob.
CR, %
Taxol
dose, mg/m2
Toxicity Blasts
% in PB·
53 i.m. 33 2 1 80!3 0 9/100
2 77 diploid 8 3 1 80!3 1 (N, P) 10/15
3 59 diploid 22 1 20 80!3 0 15/55
4 35 diploid 43 2 1 100!3 0 59/90
5 64 –5,–7 20 2 1 100!3 2 (U) 72/9b
6 38 diploid 8 1 1 100!3 0 5/nt
7 20 diploid NAc 2 1 100!2d 0 93/96
8 59 i.m. 35 3 10 100!2d 0 10/45
9 77 diploid 0 2 1 100!3 0 28/88
10 50 t(9;11) 43 2 1 125!3 1 (P) nt/nt
11 42 diploid 9 2 1 125!3 1 (D) 91/98
12 73 +8 0 3 1 125!2e 3 (U) 51/95
13 39 –5,–7 6 2 1 125!3 2 (N) 9/63
CR = Complete remission; PB = peripheral blood; N = nausea; U = ulcer; D = diarrhea; i.m. = insufficient
metaphases; nt = not tested.
a Blasts before/after one course of taxol (percentage).
b In this patient, a concomitant decrease in bone marrow blasts from 60 to 15% was noted.
c Underwent bone marrow transplantation and relapsed 4 weeks thereafter.
d Patient died before 3rd dose could be given.
e 3rd dose not given because of grade 3 toxicity (stomatitis).
if his marrow was not hypoplastic after 1 course of taxol
(3 doses) or if he or she was not in CR after 2 courses of
taxol (6 doses) with 11 week separating courses and no
more than 3 doses given per course or if the patient devel-
oped 6 grade 2 extramedullary toxicity with a !50%
decrease in the marrow leukemic infiltrate. Toxicity was
evaluated according to common NCI criteria.
A total of 13 patients with relapsed or refractory AML
was treated with taxol. All patients were heavily pre-
treated. Most patients had failed several salvage regimens
and had a low probability of obtaining CR (!1%) [8]. At
80 mg/m2 !3 (3 patients) only minor toxicities were
encountered. Six patients were treated at 100 mg/m2; in 1
of 3 evaluable patients a grade 2 stomatitis was recorded.
Four patients were treated at 125 mg/m2. All had major
toxicity: 1 patient had a severe buccal ulcer (stomatitis,
grade 3), and 1 patient each had grade 2 nausea, grade 1
peripheral neuropathy and grade 1 diarrhea. All patients
were severely immunosuppressed: 3/13 had fever of unde-
termined etiology, 1 patient each had pneumonia and
herpes zoster infection and 5 patients were treated for sep-
ticemia and/or fungemia. No patients entered CR. Only
in 1 of 11 patients some antileukemic activity (decrease of
blasts in blood and bone marrow) could be observed. Tak-
ing into account the definite toxicity observed at the dose
level of 125 mg/m2 !3, a further dose escalation does not
appear feasible in this group of patients with AML who
are heavily pretreated. Taking into account the modest
antileukemic activity observed at this dose level, a further
dose escalation also would not appear to enter patients
into CR. We conclude from this study that the schedule
proposed here for taxol (three 24-hour infusions at 1-week
interval) is no improvement as far as toxicity and antileu-
kemic activity are concerned.
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